Short Interest in Spectral Diagnostics Inc. (OTCMKTS:EDTXF) Decreases By 60.8%

Spectral Diagnostics Inc. (OTCMKTS:EDTXF) was the recipient of a large decrease in short interest in April. As of April 30th, there was short interest totaling 6,989 shares, a decrease of 60.8% from the April 15th total of 17,844 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 9,266 shares, the short-interest ratio is currently 0.8 days.

Spectral Diagnostics Price Performance

Shares of OTCMKTS:EDTXF traded down $0.02 during midday trading on Friday, hitting $1.02. The company had a trading volume of 900 shares, compared to its average volume of 11,624. The company has a market cap of $299.29 million, a price-to-earnings ratio of -10.20 and a beta of 0.09. Spectral Diagnostics has a 12-month low of $0.58 and a 12-month high of $1.31. The company has a fifty day moving average of $1.00 and a two-hundred day moving average of $0.99.

Spectral Diagnostics (OTCMKTS:EDTXF) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.01) EPS for the quarter, hitting the consensus estimate of ($0.01). The company had revenue of $0.64 million during the quarter, compared to analysts’ expectations of $0.54 million.

Spectral Diagnostics Company Profile

Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.